Navigation Links
New ways to disarm deadly South American hemorrhagic fever viruses
Date:3/8/2010

mans is unknown, Harrison says. Other segments of the receptor bind iron-bearing transferrin, but the apical domain appears to be uninvolved in that process. "We don't know the normal function of the apical domain. Obviously it didn't evolve just to give Machupo virus a way to infect humans, but that's what the virus has evolved to latch onto," he says.

Because the apical domain is not involved in the critical task of moving iron into cells, Harrison says it presents an attractive target for drugs. In theory, an antibody designed to attach to the apical domain would prevent the Machupo virus from attaching to cells, blocking infection. One possible treatment strategy, then, would be to infuse patients with such an antibody during the early stages of infection, which might slow the infection enough to let patients recover.

Harrison says the finding might also help virologists predict which of the 22 known arenaviruses might be capable of infecting humans. Only five are known to infect humans nowand all of those bind to the human transferrin receptor. Presumably the other 17 viruses produce surface proteins that are unable to bind to the human transferrin receptor, Harrison says.

For Abraham, the idea of finding a treatment for these New World hemorrhagic fevers is close to his heart. His family hails from Haiti, where there is a "huge burden of infectious diseases. I'd like to dedicate my career to studying pathogens in underserved parts of the world," he says.


'/>"/>

Contact: Andrea Widener
widenera@hhmi.org
301-215-8807
Howard Hughes Medical Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Scientists ramp up ability of poplar plants to disarm toxic pollutants
2. Ebola virus disarmed by excising a single gene
3. Disarming specialized stem cells might combat deadly ovarian cancer
4. Scripps research team blocks bacterial communication system to prevent deadly staph infections
5. Northwestern to expose most deadly infectious diseases in 3-D
6. Best treatment identified to reduce deadly Staph infections
7. Research unveils new hope for deadly childhood disease
8. Deadly genetic disease prevented before birth in zebrafish
9. Ayurvedic nightshade deadly for dengue mosquito
10. Sydney harbors deadly diet for sea creatures
11. New vaccine may give long-term defense against deadly bird flu and its variant forms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
(Date:8/3/2015)... Calif. , Aug. 3, 2015 Synaptics, ... human interface solutions, today announced that members of the ... at the Pacific Crest Global Technology Leadership Forum on ... The conference will be held at the Sonnenalp Resort ... The presentation may include forward-looking information. An audio ...
(Date:7/31/2015)... , 31 de julio de 2015 La 10 ... se celebrará por medio de BGI del 22 al 25 de ... Este año, la conferencia celebra su décimo ... ha convertido en una de las reuniones anuales más influyentes ... de las reuniones más dinámicas, entusiastas y mejores a nivel ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... Ore. After being hunted to local extinction more than ... grounds, the southern right whales of mainland New Zealand are ... for the first time that whales from a small surviving ... to the New Zealand mainland. Before the onslaught of ...
... Queen Mary, University of London, sheds new light on why ... can suffer organ damage in parts of the body which ... today in Nature Immunology *, examines the way certain ... to defend damaged organs against injury or infection. This ...
... therapy technique called genome editing that hones in on ... the blood clotting disorder hemophilia in mice. This is ... and repairs a genetic defect, has been done in ... As such, it represents an important step forward in ...
Cached Biology News:Fighting back from extinction, New Zealand right whale is returning home 2Fighting back from extinction, New Zealand right whale is returning home 3Rogue blood cells may contribute to post-surgery organ damage 2Genome editing, a next step in genetic therapy, corrects hemophilia in animals 2Genome editing, a next step in genetic therapy, corrects hemophilia in animals 3
(Date:9/1/2015)...   Medfusion, Inc., a patient engagement ... and patients, today announced a $3 million investment ... venture capital firms.   "We welcome ... City Venture Partners and Hatteras Venture Partners," said ... Chairman. "Both firms, experience working at the intersection ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... announced the release of a groundbreaking new version of its flagship DNA design ... methodology breaks down complex DNA sequences into numerous genetic parts, which in turn ...
(Date:8/31/2015)... ... 31, 2015 , ... In recent years, biodegradable plastics have ... carbon footprints and compostability. These properties can help in limiting the degradation of ... of applications, the market for biodegradable plastics can be broadly segmented into packaging, ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/53wxp3/israel_biomedical ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Sensors market is estimated at $0.19 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
Breaking Biology Technology:Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2
... Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced ... approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme ... patients refractory to conventional therapy.  Chronic gout that is ... failed to normalize serum uric acid and whose signs ...
... DSM Biomedical , a global leader in biomedical ... today announced the company has extended its partnership with ... a dynamic stabilization system for the spine. Spinelab,s Elaspine™ ... for the degenerative lumbar spine, uses Bionate ® ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced ... and European fidaxomicin Phase 3 clinical trials in patients ... 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ... Cornely, M.D., of the University of Cologne, presented data ...
Cached Biology Technology:FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 2FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 3FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 4FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 5FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 6FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 7FDA Approves KRYSTEXXA™ (pegloticase) for the Treatment of Chronic Gout in Adult Patients Refractory to Conventional Therapy 8DSM Biomedical Announces Continued Partnership with Spinelab 2DSM Biomedical Announces Continued Partnership with Spinelab 3Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC 2Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC 3Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC 4Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC 5